In addition, MAGEB1, which also had a high BPH sera immunoreactivity in our study was previously found to exhibit low immunoreactivity to PCa after administration of Lenalidomide (a thalidomide analogue) to PCa patients in a randomized phase II trial [65]. Here, MAGEB1 is linked to benign prostatic hyperplasia.